Skip to content
OpenCapital
Get started

Summit Therapeutics SMMT Q2 2025 earnings

Reported August 11, 2025 · After market close

Diluted EPS-$0.76Miss by $0.67
EPS estimate-$0.09

Next report

Aug 10, 2026 (In 4 weeks)
Revenue estimate$108.8K
EPS estimate-$0.26

Financials

Q2 2025

Income statement

See full
Net income-$565.7M-837%
EPS (diluted)-$0.76-744%

Balance sheet

See full
Cash & equivalents$4.3M-72.8%
Total debt$5.6M-36.2%
Total equity$259.4M+33.0%
Total assets$324.0M-5.2%

Cash flow

See full
Operating cash flow-$66.7M-102%
CapEx--100%
Free cash flow-$66.7M-102%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$15.54B+180%
Enterprise value$15.54B+181%

Returns & leverage

See full
Return on equity-328.3%-603pp
Debt / equity0×0.0×
Current ratio5.1×+2.8×

Versus estimates

Diluted EPS

Q1 2026-$0.24Beat by $0.09Q4 2025-$0.29Miss by $0.19Q3 2025-$0.31Miss by $0.13
Q2 2025-$0.76Miss by $0.67
Q1 2025-$0.09Beat by $0.00Q4 2024-$0.08Beat by $0.00

Ask the moment Summit Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Summit Therapeutics report Q2 2025 earnings?
Summit Therapeutics (SMMT) reported Q2 2025 earnings on August 11, 2025 after market close.
What were Summit Therapeutics's Q2 2025 revenue and EPS?
Summit Therapeutics reported diluted EPS of $-0.76 for Q2 2025.
Did Summit Therapeutics beat estimates in Q2 2025?
EPS missed the consensus estimate of $-0.09 by $0.67.
How did Summit Therapeutics's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS declined 1420.0% from $-0.05.
Where can I find Summit Therapeutics's Q2 2025 SEC filings?
You can read the 10-Q periodic report (0001599298-25-000126) directly on SEC EDGAR. The filing index links above go to sec.gov.